References
- Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell. 1993; 72(4): 477-480.
- Alfirevic Z, Simundic AM, Nikolac N, Sobocan N, Alfirevic I, Stefanovic M, et al. Frequency of factor II G20210A, factor V Leiden, MTHFR C677T and PAI-1 5G/4G polymorphism in patients with venous thromboembolism: Croatian case control study. Biochemia Medica. 2010; 20(2): 229-235.
- Segers K, Dahlback B, Gerry AFN. Coagulation factor V and thrombophilia: Background and mechanisms. Thromb Haemost. 2007; 98(3): 530-542.
- Katcharin A, Napaporn A, Timaluck S, Pantep A. Prevalence of factor V Leiden (G1691A) and prothrombin gene mutation (G20210A) among different ethnic group in Thai hospitals. J Hematol Transfus Med. 2012; 22(2): 115-120.
- Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C). Blood. 1995; 85(6): 1504-1508.
- Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997; 277(16): 1305-1307.
- Herrmann FH, Koesling M, Schrŏder W, Altman R, Jiménez Bonilla R, Lopaciuk S, et al. Prevalence of factor V Leiden mutation in various population. Genet Epidemiol. 1997; 14(4): 403-411.
- Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996; 88(10): 3698-3703.
- Bavikatty N, Kileen A, Akel N, Normolle D, Schmaier A. Association of the prothrombin G20210A mutation with factor V Leiden in a midwestern American population. Am J Clin Pathol. 2000; 114(2): 272-275.
- Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: C677T mutation in the methylene-tetrahydofolate reductase gene and risk of venous throm-boembolism. Br J Haematol. 1997; 97(4): 804-806.
- den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis. N Engl J Med. 2005; 3(2): 292-299.
- Karic A, Terzic R, Jerkic Z, Mustedanagic-Mujanovic J. The frequency of C677T methylentetra-hidrofolate reductase (MTHFR) polymorphism in Southern East Bosnian population. J Biomet Biostat. 2013; 4(4): 1-4.
- Adler G, Agnieszka G, Valjevac A, Czerska E, Kiseljakovic E, Salkic N. Prevalence of genetic prothrombotic risk factors: 1691G>A FV, 20210G>A PT and 677 C>T MTHFR mutations in Bosnian population. Ann Hum Biol. 2014; 42(6): 576-580.
- Bertina RM, Koelman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation facto V associated with resistance to activated protein C. Nature. 1996; 369(6475): 64-67.
- Froost P, Blom HJ, Milos R, Gazette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylene-tetrahydrofolatereductase. Nat Genet. 1995; 10(1): 111-113.
- McHugh M. The odds ratio: Calculation, usage and inerpretation. Biochemia Medica. 2009; 19(2): 120-126.
- Kejzer M, den Hajer M, Blom HJ, Bos GMJ, Willems HPJ, Gerrits WBJ, et al. Interaction between hyperhomocysteinemia, mutated methylenetetra-hydrofolate reductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost. 2002; 88(5): 72-78.
- Meglic L, Stegnar M, Milanez T, Bozic M, Peterlin B, Peternel P, et al. Factor V Leiden, prothrombin 20210 G>A, methylenetetrahydro-folate reductase 677C>T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy related venous thromboembolism. Eur J Obstet Gynecol Reprod Biol. 2003; 111(2): 157-163.
- Berge E, Haug KB, Sandset EC, Haughbro KK, Turkovic M, Sandset PM. The factor V Leiden, prothrombin gene 20210GA, methylenetetra-hydrofolate reductase 677CT and platelet glycoprotein IIIa 1565TC mutations in patients with acute ishemic stroke and atrial fibrillation. Stroke. 2007; 38(3): 106-171.
- Pauer H, Voigt-Tschirschwitz T, Hinney B, Burfeind P, Wolf C, Emons G, et al. Analyzes of three common thrombophilic gene mutations in German women with recurrent abortions. Acta Obstet Gynecol Scand. 2003; 82(10): 942-947.
- Koster T, Roosendal FR, de Ronde H, Riet E, Vandenbroucke JP, Bertina R. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilila study. Lancet. 1993; 342(8886-8887): 1503-1506.
- Coen D, Zadro R, Honovic, Banfic Lj, Rukavina-Stavljenic A. Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism. Croat Med J. 2001; 42(4): 488-492.
- Đorđevic V, Rakicevic Lj, Mikovic D, Kovac M, Miljic P, Radojkovic D, et al. Prevalence of factor V Leiden, factor V Cambridge, factor II G20210A and methylenetetra-hydrofolatere-ductase C677T mutations in healthy and thrombophilic Serbian populations. Acta Haematol. 2004; 112(4): 227-229.
- Arsov T, Miladinova D, Spiroski M. Factor V Leiden is associated with higher risk deep venous thrombosis of large blood vessels. Croat Med J. 2006; 47(3): 433-439.
- Jadaon MM. Epidemiology of prothrombin G20210A mutation in the Mediterranean region. Mediterr J Hematol Infect Dis. 2011; 3(1): e2011054. doi: 10.4084/MJHID.2011.054.
- Isotalo PA, Donnely JG. Prevalence of methylenetetra-hydrofolatereductase mutations in patients with venous thrombosis. Mol Diagn. 2000; 5(1): 59-66.
- Moglinicka-Nizankowska E, Adamek L, Grzanka P, Domagala TB, Sanak M, Krzanowski M, et al. Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis. Eur Respir J. 2003; 21(1): 25-30.
- D’Angelo A, Beltramentti C. Venous disease. In: Carmel R, Jacobsen DW, Eds. Homocysteine in Health and Disease. Cambridge, Cambridgeshire, UK: Cambridge University Press. 2001:401-414.
- Tsai AW, Cushman M, Tsai MY, Heckbert SR, Rosamond WD, Aleksic N, et al. Serum homocysteine, thermolabile variant of methylenetetra-hydrofolat reductase (MTHFR) and venous thromboembolism: Longitudinal investigation of thromboembolism etiology (LITE). Am J Hematol. 2003; 72(3): 192-200.
- Beyan C, Beyan E. MTHFR 677 CT gene polymorphism is not a risk factor for venous thromboembolism. Çukurova Med J. 2014; 39(1): 189-190.
- Ehrenforth S, von Fepka-Prondsinski M, Aygoren-Pursun E, Nowak-Gottl U, Scharrer I, Ganser A. Study of the prothrombin gene 20210GA variant in FV:Q506 car-riers in the relationship to the presence or absence of juvenile venous thromboemolism. Arterioscler Thromb Vasc Biol. 1999; 19(2): 276-280.
- Zoller B, Svanson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994; 94(6): 2521-2524.
- Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, et al. The heterozygous 20210G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilia and is not increased in frequency of artery disease. Arterioscler Thromb Vasc Biol. 1997; 17(11): 2418-2422.
- De Stefano V, Martinelli I, Mannuccio P, Paciaroni K, Chiusolo P, Casorelli I, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999; 341(11): 801-806.
- Simone B, De Stefano V, Leoncini E, Zacho, Martinelli I, Emmerich J, et al. Risk of venous thromboembolism associated with single and combined effects of factor V Leiden, prothrombin 20210A and methylenetetra-hydrofolate reductase C677T: A meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013; 28(8): 621-647.